Skip to Main Content

Opinions+

Perspectives on issues affecting biopharma and health care.

Latest

Opinions+ Kolaleh Eskandanian

STAT Plus: Medicare’s new RAPID pathway is a breakthrough for adults. Children are still waiting

Neurotransmissions Jason Karlawish

STAT Plus: Ambiguous loss: a peculiar kind of grief in dementia care

Opinions+ Dennis Kwok

STAT Plus: China’s strict new supply chain regulations could create massive problems for Western biopharma companies

Lab Dish Paul Knoepfler

STAT Plus: Did Kennedy just stack the deck on FDA oversight of peptides?

Opinions+ Lawrence K. Altman

STAT Plus: I’m an expert on presidential health. The 25th Amendment is not an option for removing Trump

Lab Dish Paul Knoepfler

STAT Plus: Landmines await Vinay Prasad’s successor at the FDA

Opinions+ Glenn Steele Jr.

STAT Plus: Former Geisinger CEO: U.S. health systems must replace huge numbers of people with AI

The Workup Vishal Khetpal

STAT Plus: Cardiology’s finally prioritizing prevention — but what will it look like?

All Coverage

Neurotransmissions Jason Karlawish

STAT Plus: How surrealism helps us make sense of and live with dementia

Lab Dish Paul Knoepfler

STAT Plus: 6 key dilemmas as human embryo models get ever closer to the real thing

Advertisement

Opinions+ Elise Felicione

I tried to design a clinical trial for a supplement. 5 things got in the way

Opinions+ Ken Cohen

STAT Plus: Optum CMO: Doctors must take responsibility for patient outcomes

Opinions+ Morish Shah and Ami Bhatt

STAT Plus: Sometimes, it would be unethical not to use AI in medicine

Neurotransmissions Jason Karlawish

STAT Plus: If you have Alzheimer’s disease, who will take part in your care?

Opinions+ Barbara Levy and Badrinath Konety

STAT Plus: Medicare may start covering multi-cancer early detection tests. It should proceed with caution

Lab Dish Paul Knoepfler

STAT Plus: Excitement and wariness as FDA shifts to much more flexible cell and gene therapy oversight

The Workup Vishal Khetpal

STAT Plus: CMS’ new MAHA ELEVATE innovation model has a fundamental flaw

Opinions+ Katherine E. Goodman and Daniel Morgan

STAT Plus: After FDA’s pivot on clinical AI, we need AI safety research more than ever

Neurotransmissions Jason Karlawish

STAT Plus: What Ozempic might tell us about the future of Alzheimer’s

Opinions+ John L. LaMattina

STAT Plus: I’m the former head of Pfizer R&D. I’m very worried about biopharma’s future

Lab Dish Paul Knoepfler

STAT Plus: FDA drug center’s new acting director fits a pattern of risky, internal contradictions among agency leadership

Opinions+ Claire D’Abreu-Hayling

STAT Plus: Sandoz chief scientific officer: What is truly necessary to establish biosimilarity?

Neurotransmissions Jason Karlawish

STAT Plus: Tech-enabled caregiving can help dementia patients stay at home — perhaps for too long

The Workup Vishal Khetpal

STAT Plus: Every doctor needs a basic level of AI literacy

Pharma Paul Hudson

STAT Plus: Sanofi CEO: How we’re measuring AI success

Lab Dish Paul Knoepfler

What will be born of the marriage of de-extinction firm Colossal and animal cloning biotech Viagen?

Opinions+ Jama Pitman

STAT Plus: FDA criticism of MDMA-assisted therapy is an opportunity for psychedelic medicine

Opinions+ Tim Scott

STAT Plus: U.S. biomedical innovation must not go the way of semiconductors and shipbuilding

Neurotransmissions Jason Karlawish

STAT Plus: All of a sudden, dementia treatment is becoming very exciting